Ping-Ching Hsu
Concepts (523)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Helicobacter pylori | 11 | 2014 | 74 | 2.290 |
Why?
| Helicobacter Infections | 9 | 2014 | 73 | 2.180 |
Why?
| Hepatitis B, Chronic | 7 | 2014 | 15 | 1.390 |
Why?
| Smoking | 5 | 2016 | 552 | 1.320 |
Why?
| Tumor Necrosis Factor-alpha | 6 | 2014 | 435 | 1.280 |
Why?
| Carcinoma, Non-Small-Cell Lung | 5 | 2021 | 164 | 1.200 |
Why?
| Hepatitis B virus | 5 | 2014 | 24 | 1.190 |
Why?
| Menthol | 2 | 2016 | 17 | 1.140 |
Why?
| Metabolome | 2 | 2016 | 109 | 0.940 |
Why?
| Nicotine | 2 | 2016 | 205 | 0.900 |
Why?
| Lung Neoplasms | 5 | 2021 | 643 | 0.900 |
Why?
| Carcinoma, Hepatocellular | 8 | 2014 | 203 | 0.890 |
Why?
| Liver Neoplasms | 9 | 2014 | 352 | 0.860 |
Why?
| Spermatozoa | 3 | 2007 | 28 | 0.810 |
Why?
| Middle Aged | 46 | 2021 | 13082 | 0.790 |
Why?
| Peptic Ulcer | 3 | 2010 | 13 | 0.740 |
Why?
| Apoptosis | 6 | 2014 | 1302 | 0.730 |
Why?
| Induction Chemotherapy | 1 | 2019 | 59 | 0.690 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 5 | 2012 | 21 | 0.690 |
Why?
| Membrane Glycoproteins | 3 | 2005 | 270 | 0.670 |
Why?
| Lymphocyte Activation | 3 | 2010 | 197 | 0.670 |
Why?
| Metabolomics | 2 | 2016 | 149 | 0.660 |
Why?
| Aged | 35 | 2021 | 10060 | 0.640 |
Why?
| Proton Pump Inhibitors | 2 | 2010 | 84 | 0.630 |
Why?
| Male | 56 | 2021 | 27347 | 0.620 |
Why?
| Cisplatin | 3 | 2019 | 351 | 0.620 |
Why?
| Apoptosis Regulatory Proteins | 5 | 2010 | 96 | 0.610 |
Why?
| Hepatitis B Core Antigens | 2 | 2014 | 6 | 0.600 |
Why?
| Polychlorinated Biphenyls | 3 | 2007 | 26 | 0.590 |
Why?
| Glucuronates | 1 | 2016 | 21 | 0.580 |
Why?
| Female | 50 | 2021 | 28471 | 0.580 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 1060 | 0.560 |
Why?
| Testis | 2 | 2007 | 65 | 0.560 |
Why?
| Gastritis | 2 | 2007 | 36 | 0.550 |
Why?
| Up-Regulation | 7 | 2014 | 509 | 0.540 |
Why?
| Gastrointestinal Hemorrhage | 7 | 2014 | 80 | 0.540 |
Why?
| Genetic Predisposition to Disease | 3 | 2015 | 570 | 0.540 |
Why?
| Humans | 68 | 2021 | 54391 | 0.520 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2012 | 40 | 0.520 |
Why?
| Adult | 33 | 2019 | 14207 | 0.510 |
Why?
| Endoscopy, Digestive System | 2 | 2012 | 53 | 0.490 |
Why?
| Immunity, Innate | 1 | 2014 | 114 | 0.460 |
Why?
| Anti-Bacterial Agents | 6 | 2014 | 825 | 0.460 |
Why?
| Esophageal and Gastric Varices | 6 | 2012 | 12 | 0.450 |
Why?
| Lymphoma, B-Cell, Marginal Zone | 2 | 2010 | 22 | 0.450 |
Why?
| Cholecystolithiasis | 1 | 2012 | 1 | 0.450 |
Why?
| Bile Duct Diseases | 1 | 2012 | 11 | 0.440 |
Why?
| Choledocholithiasis | 1 | 2012 | 12 | 0.440 |
Why?
| Taiwan | 7 | 2014 | 26 | 0.440 |
Why?
| Disease Models, Animal | 3 | 2014 | 1647 | 0.440 |
Why?
| Antigens, Bacterial | 2 | 2010 | 63 | 0.430 |
Why?
| Duodenal Ulcer | 3 | 2009 | 13 | 0.420 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2012 | 116 | 0.400 |
Why?
| Galectin 3 | 1 | 2011 | 15 | 0.400 |
Why?
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2010 | 5 | 0.390 |
Why?
| Membrane Microdomains | 1 | 2010 | 15 | 0.390 |
Why?
| Tobacco Products | 1 | 2013 | 115 | 0.380 |
Why?
| Aged, 80 and over | 12 | 2021 | 3431 | 0.380 |
Why?
| Ticlopidine | 1 | 2010 | 57 | 0.370 |
Why?
| T-Lymphocytes | 2 | 2010 | 374 | 0.370 |
Why?
| NF-kappa B | 3 | 2010 | 336 | 0.370 |
Why?
| Gastric Juice | 1 | 2010 | 7 | 0.370 |
Why?
| Macrophage Inflammatory Proteins | 2 | 2007 | 4 | 0.370 |
Why?
| Endoscopy, Gastrointestinal | 6 | 2012 | 75 | 0.370 |
Why?
| Chemotaxis, Leukocyte | 2 | 2007 | 20 | 0.370 |
Why?
| Arthritis, Rheumatoid | 1 | 2011 | 130 | 0.370 |
Why?
| alpha 1-Antitrypsin | 1 | 2010 | 19 | 0.360 |
Why?
| Esophagitis | 1 | 2009 | 10 | 0.360 |
Why?
| Stomach Neoplasms | 2 | 2010 | 174 | 0.360 |
Why?
| Antigens, CD | 1 | 2010 | 242 | 0.340 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2010 | 179 | 0.340 |
Why?
| Serologic Tests | 1 | 2008 | 28 | 0.340 |
Why?
| Breath Tests | 1 | 2008 | 44 | 0.340 |
Why?
| Bacterial Proteins | 3 | 2010 | 456 | 0.340 |
Why?
| Neoplasm Staging | 5 | 2021 | 805 | 0.340 |
Why?
| Anti-Ulcer Agents | 2 | 2005 | 20 | 0.330 |
Why?
| Urea | 1 | 2008 | 83 | 0.330 |
Why?
| Antibodies, Antinuclear | 2 | 2007 | 19 | 0.330 |
Why?
| Sulfoxides | 2 | 2005 | 28 | 0.330 |
Why?
| Chemokines, CC | 2 | 2007 | 9 | 0.330 |
Why?
| Signal Transduction | 7 | 2014 | 1752 | 0.320 |
Why?
| Benzimidazoles | 2 | 2005 | 54 | 0.320 |
Why?
| HLA-DR2 Antigen | 1 | 2007 | 1 | 0.320 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2011 | 552 | 0.320 |
Why?
| Gastric Mucosa | 2 | 2007 | 59 | 0.320 |
Why?
| Atherosclerosis | 1 | 2010 | 249 | 0.310 |
Why?
| Amoxicillin | 4 | 2014 | 22 | 0.310 |
Why?
| Receptors, Chemokine | 1 | 2007 | 13 | 0.310 |
Why?
| Cell Proliferation | 2 | 2014 | 1097 | 0.300 |
Why?
| Prospective Studies | 9 | 2019 | 2606 | 0.300 |
Why?
| Enzyme Activation | 5 | 2010 | 328 | 0.300 |
Why?
| Liver Cirrhosis | 6 | 2012 | 218 | 0.300 |
Why?
| Liver | 7 | 2014 | 1226 | 0.290 |
Why?
| Pseudarthrosis | 1 | 2006 | 1 | 0.290 |
Why?
| Arthritis, Psoriatic | 1 | 2006 | 11 | 0.290 |
Why?
| Hepatitis C, Chronic | 1 | 2007 | 89 | 0.290 |
Why?
| Polybrominated Biphenyls | 1 | 2006 | 1 | 0.290 |
Why?
| Lupus Erythematosus, Systemic | 2 | 2004 | 76 | 0.290 |
Why?
| Phenyl Ethers | 1 | 2006 | 5 | 0.290 |
Why?
| Epididymis | 1 | 2006 | 8 | 0.290 |
Why?
| Flame Retardants | 1 | 2006 | 2 | 0.290 |
Why?
| Mass Screening | 1 | 2010 | 370 | 0.280 |
Why?
| Spinal Fractures | 1 | 2006 | 41 | 0.280 |
Why?
| Monocytes | 4 | 2014 | 156 | 0.280 |
Why?
| Peroxidase | 1 | 2005 | 19 | 0.270 |
Why?
| Viral Core Proteins | 1 | 2005 | 6 | 0.260 |
Why?
| Gallstones | 4 | 2009 | 14 | 0.260 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2010 | 158 | 0.260 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2007 | 172 | 0.260 |
Why?
| Naphthoquinones | 1 | 2004 | 14 | 0.250 |
Why?
| DNA | 3 | 2015 | 581 | 0.250 |
Why?
| Mitochondria, Liver | 1 | 2005 | 86 | 0.250 |
Why?
| Hepacivirus | 1 | 2005 | 127 | 0.240 |
Why?
| Immunologic Factors | 1 | 2005 | 130 | 0.240 |
Why?
| Antiviral Agents | 3 | 2014 | 188 | 0.230 |
Why?
| Cachexia | 1 | 2003 | 24 | 0.230 |
Why?
| Triiodothyronine | 1 | 2003 | 29 | 0.230 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 142 | 0.230 |
Why?
| Young Adult | 5 | 2019 | 4318 | 0.230 |
Why?
| Enzyme Inhibitors | 1 | 2005 | 446 | 0.220 |
Why?
| Carrier Proteins | 1 | 2005 | 360 | 0.220 |
Why?
| Sex Factors | 4 | 2016 | 766 | 0.220 |
Why?
| Reactive Oxygen Species | 4 | 2007 | 491 | 0.220 |
Why?
| Lipopolysaccharides | 5 | 2008 | 200 | 0.210 |
Why?
| Follow-Up Studies | 8 | 2020 | 2390 | 0.210 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2004 | 181 | 0.210 |
Why?
| Risk Assessment | 5 | 2016 | 1362 | 0.210 |
Why?
| Metronidazole | 2 | 2012 | 30 | 0.210 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 3 | 2014 | 21 | 0.210 |
Why?
| Antibodies, Monoclonal | 2 | 2020 | 564 | 0.210 |
Why?
| Clarithromycin | 3 | 2014 | 40 | 0.210 |
Why?
| Organometallic Compounds | 2 | 2012 | 47 | 0.200 |
Why?
| Sigmoidoscopy | 2 | 2014 | 10 | 0.200 |
Why?
| Colorectal Neoplasms | 1 | 2004 | 237 | 0.200 |
Why?
| Virus Replication | 2 | 2014 | 143 | 0.200 |
Why?
| Cells, Cultured | 6 | 2015 | 1737 | 0.200 |
Why?
| Age Factors | 4 | 2016 | 1199 | 0.200 |
Why?
| Cross-Sectional Studies | 3 | 2016 | 1696 | 0.200 |
Why?
| Treatment Outcome | 12 | 2021 | 5612 | 0.190 |
Why?
| Animals | 12 | 2014 | 14409 | 0.190 |
Why?
| Reproducibility of Results | 2 | 2016 | 1301 | 0.190 |
Why?
| Mice | 8 | 2014 | 6428 | 0.190 |
Why?
| Drug Therapy, Combination | 7 | 2013 | 426 | 0.190 |
Why?
| Adenine | 2 | 2013 | 44 | 0.180 |
Why?
| Cohort Studies | 2 | 2019 | 1546 | 0.180 |
Why?
| Sulfones | 1 | 2019 | 24 | 0.180 |
Why?
| Chemoradiotherapy | 1 | 2020 | 42 | 0.180 |
Why?
| Interferon-gamma | 3 | 2012 | 195 | 0.180 |
Why?
| Salvage Therapy | 1 | 2020 | 145 | 0.180 |
Why?
| Oncogene Proteins, Fusion | 1 | 2019 | 60 | 0.180 |
Why?
| Recurrence | 6 | 2012 | 692 | 0.170 |
Why?
| Prognosis | 6 | 2021 | 2126 | 0.170 |
Why?
| Sphincterotomy, Endoscopic | 3 | 2009 | 15 | 0.170 |
Why?
| Multivariate Analysis | 4 | 2016 | 643 | 0.170 |
Why?
| Pyrimidines | 1 | 2019 | 196 | 0.160 |
Why?
| Administration, Oral | 1 | 2019 | 461 | 0.160 |
Why?
| Platelet Aggregation | 2 | 2010 | 82 | 0.160 |
Why?
| Adolescent | 5 | 2016 | 6900 | 0.160 |
Why?
| Somatostatin | 2 | 2008 | 26 | 0.150 |
Why?
| Pancreatitis | 2 | 2008 | 58 | 0.150 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 674 | 0.150 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2010 | 170 | 0.150 |
Why?
| Sensitivity and Specificity | 2 | 2010 | 922 | 0.150 |
Why?
| Nadolol | 2 | 2008 | 3 | 0.150 |
Why?
| Carcinoma, Squamous Cell | 1 | 2020 | 385 | 0.140 |
Why?
| Risk Factors | 5 | 2014 | 3937 | 0.140 |
Why?
| Caspase 9 | 2 | 2007 | 20 | 0.140 |
Why?
| Caspase 3 | 2 | 2007 | 135 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 5 | 2007 | 1476 | 0.130 |
Why?
| Injections, Intraperitoneal | 2 | 2007 | 59 | 0.130 |
Why?
| Alcohol Drinking | 2 | 2009 | 259 | 0.130 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 474 | 0.130 |
Why?
| Animals, Newborn | 2 | 2007 | 396 | 0.130 |
Why?
| Rats, Sprague-Dawley | 4 | 2014 | 1664 | 0.130 |
Why?
| Membrane Potentials | 2 | 2006 | 139 | 0.130 |
Why?
| Sperm Count | 2 | 2006 | 10 | 0.130 |
Why?
| Sperm Motility | 2 | 2006 | 13 | 0.130 |
Why?
| Severity of Illness Index | 5 | 2012 | 1082 | 0.130 |
Why?
| Cell Line, Tumor | 3 | 2010 | 1551 | 0.130 |
Why?
| Adenosine Diphosphate | 2 | 2004 | 23 | 0.130 |
Why?
| P-Selectin | 2 | 2004 | 33 | 0.130 |
Why?
| Guanine | 3 | 2014 | 42 | 0.120 |
Why?
| Mutation | 1 | 2021 | 1504 | 0.120 |
Why?
| Leukocytes | 2 | 2004 | 86 | 0.120 |
Why?
| Toll-Like Receptor 9 | 1 | 2014 | 11 | 0.120 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2014 | 20 | 0.120 |
Why?
| Caspases | 2 | 2005 | 146 | 0.120 |
Why?
| Intestinal Polyps | 1 | 2014 | 9 | 0.120 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2007 | 251 | 0.120 |
Why?
| PTEN Phosphohydrolase | 1 | 2014 | 61 | 0.120 |
Why?
| Thymidine | 1 | 2013 | 18 | 0.120 |
Why?
| Organophosphonates | 1 | 2013 | 5 | 0.120 |
Why?
| Aryl Hydrocarbon Hydroxylases | 2 | 2011 | 70 | 0.120 |
Why?
| Thromboembolism | 1 | 2014 | 56 | 0.120 |
Why?
| Immunocompetence | 1 | 2013 | 19 | 0.120 |
Why?
| Hysterectomy | 1 | 2014 | 89 | 0.120 |
Why?
| Dobutamine | 2 | 2003 | 24 | 0.120 |
Why?
| Toll-Like Receptor 3 | 1 | 2013 | 9 | 0.120 |
Why?
| Adrenergic beta-Agonists | 2 | 2003 | 43 | 0.120 |
Why?
| Mice, Inbred C57BL | 4 | 2013 | 2001 | 0.120 |
Why?
| Interferons | 1 | 2013 | 44 | 0.120 |
Why?
| Chemokine CCL2 | 2 | 2003 | 79 | 0.110 |
Why?
| Area Under Curve | 2 | 2012 | 205 | 0.110 |
Why?
| Cyclooxygenase 2 | 2 | 2014 | 49 | 0.110 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2009 | 87 | 0.110 |
Why?
| Warfarin | 1 | 2014 | 87 | 0.110 |
Why?
| Gene Frequency | 2 | 2011 | 120 | 0.110 |
Why?
| Pyrazoles | 1 | 2014 | 110 | 0.110 |
Why?
| Secondary Prevention | 2 | 2010 | 89 | 0.110 |
Why?
| Protein Transport | 2 | 2010 | 195 | 0.110 |
Why?
| ROC Curve | 2 | 2012 | 259 | 0.110 |
Why?
| Ofloxacin | 1 | 2012 | 10 | 0.110 |
Why?
| Genotype | 2 | 2013 | 600 | 0.110 |
Why?
| Interleukin-6 | 2 | 2012 | 315 | 0.110 |
Why?
| Sulfonamides | 1 | 2014 | 146 | 0.110 |
Why?
| Quality Control | 1 | 2013 | 101 | 0.110 |
Why?
| Observer Variation | 1 | 2013 | 139 | 0.110 |
Why?
| Cholecystectomy | 1 | 2012 | 32 | 0.110 |
Why?
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 7 | 0.110 |
Why?
| Hepatitis B | 2 | 2010 | 27 | 0.110 |
Why?
| Cell Line | 5 | 2012 | 1152 | 0.110 |
Why?
| Rats | 4 | 2014 | 3419 | 0.110 |
Why?
| Elasticity Imaging Techniques | 1 | 2012 | 25 | 0.110 |
Why?
| Cesarean Section | 1 | 2014 | 179 | 0.110 |
Why?
| Blood Platelets | 2 | 2004 | 268 | 0.110 |
Why?
| Flow Cytometry | 4 | 2014 | 547 | 0.110 |
Why?
| Interleukins | 1 | 2012 | 39 | 0.100 |
Why?
| Pregnancy | 3 | 2014 | 2639 | 0.100 |
Why?
| Feasibility Studies | 1 | 2013 | 398 | 0.100 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 314 | 0.100 |
Why?
| Oligonucleotide Probes | 1 | 2011 | 21 | 0.100 |
Why?
| Tandem Mass Spectrometry | 1 | 2013 | 248 | 0.100 |
Why?
| Mice, Inbred BALB C | 1 | 2012 | 370 | 0.100 |
Why?
| Tetracycline | 1 | 2011 | 21 | 0.100 |
Why?
| Spleen | 1 | 2012 | 187 | 0.100 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2013 | 377 | 0.100 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 2011 | 44 | 0.100 |
Why?
| Nucleic Acid Hybridization | 1 | 2011 | 54 | 0.100 |
Why?
| Retrospective Studies | 4 | 2021 | 6459 | 0.100 |
Why?
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2010 | 3 | 0.100 |
Why?
| Anticoagulants | 1 | 2014 | 270 | 0.100 |
Why?
| Mitochondria | 2 | 2006 | 490 | 0.100 |
Why?
| Gene Expression Regulation | 4 | 2015 | 1063 | 0.100 |
Why?
| Jurkat Cells | 1 | 2010 | 34 | 0.100 |
Why?
| Platelet Function Tests | 1 | 2010 | 20 | 0.100 |
Why?
| Immunohistochemistry | 2 | 2013 | 1090 | 0.100 |
Why?
| Polymorphism, Genetic | 2 | 2011 | 193 | 0.100 |
Why?
| Drug Administration Schedule | 5 | 2013 | 401 | 0.090 |
Why?
| Organ Size | 2 | 2012 | 237 | 0.090 |
Why?
| Drug Interactions | 1 | 2010 | 206 | 0.090 |
Why?
| Disease Progression | 3 | 2014 | 915 | 0.090 |
Why?
| bcl-X Protein | 1 | 2010 | 61 | 0.090 |
Why?
| Gene Expression Profiling | 1 | 2015 | 1141 | 0.090 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 74 | 0.090 |
Why?
| Lymphoma, B-Cell | 1 | 2010 | 62 | 0.090 |
Why?
| Areca | 1 | 2009 | 2 | 0.090 |
Why?
| Gallbladder Neoplasms | 1 | 2009 | 5 | 0.090 |
Why?
| Tumor Cells, Cultured | 2 | 2014 | 477 | 0.090 |
Why?
| B-Lymphocytes | 1 | 2010 | 176 | 0.090 |
Why?
| Logistic Models | 2 | 2009 | 991 | 0.090 |
Why?
| Cell Differentiation | 1 | 2012 | 720 | 0.090 |
Why?
| bcl-2-Associated X Protein | 2 | 2007 | 73 | 0.090 |
Why?
| Catechols | 1 | 2008 | 7 | 0.090 |
Why?
| Capsules | 1 | 2008 | 34 | 0.090 |
Why?
| Osteoclasts | 1 | 2012 | 469 | 0.080 |
Why?
| Albumins | 1 | 2009 | 39 | 0.080 |
Why?
| Endotoxins | 1 | 2009 | 37 | 0.080 |
Why?
| Body Mass Index | 2 | 2009 | 712 | 0.080 |
Why?
| Bilirubin | 2 | 2007 | 49 | 0.080 |
Why?
| Carbon Isotopes | 1 | 2008 | 71 | 0.080 |
Why?
| DNA, Viral | 3 | 2014 | 143 | 0.080 |
Why?
| Antibodies, Bacterial | 1 | 2008 | 38 | 0.080 |
Why?
| Isosorbide Dinitrate | 1 | 2008 | 1 | 0.080 |
Why?
| Peritonitis | 1 | 2009 | 33 | 0.080 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2008 | 83 | 0.080 |
Why?
| B-Cell Activating Factor | 1 | 2008 | 3 | 0.080 |
Why?
| Chi-Square Distribution | 1 | 2009 | 318 | 0.080 |
Why?
| Intestinal Mucosa | 2 | 2007 | 259 | 0.080 |
Why?
| Adenomyoma | 1 | 2008 | 2 | 0.080 |
Why?
| Jejunal Neoplasms | 1 | 2008 | 4 | 0.080 |
Why?
| Prevalence | 2 | 2009 | 1025 | 0.080 |
Why?
| Digestive System Surgical Procedures | 1 | 2008 | 36 | 0.080 |
Why?
| Dietary Fats | 1 | 2009 | 142 | 0.080 |
Why?
| Immunoglobulin G | 1 | 2008 | 227 | 0.080 |
Why?
| Antibody Specificity | 1 | 2007 | 48 | 0.080 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 99 | 0.080 |
Why?
| Adrenergic beta-Antagonists | 1 | 2008 | 105 | 0.080 |
Why?
| Ligands | 2 | 2006 | 229 | 0.080 |
Why?
| Vasodilator Agents | 1 | 2008 | 111 | 0.080 |
Why?
| Chemokine CCL20 | 1 | 2007 | 1 | 0.080 |
Why?
| Receptors, CXCR3 | 1 | 2007 | 3 | 0.080 |
Why?
| Receptors, CCR6 | 1 | 2007 | 4 | 0.080 |
Why?
| Receptors, CCR5 | 1 | 2007 | 9 | 0.080 |
Why?
| Phenotype | 1 | 2010 | 819 | 0.080 |
Why?
| Survival Rate | 3 | 2020 | 954 | 0.080 |
Why?
| T-Lymphocyte Subsets | 1 | 2007 | 41 | 0.080 |
Why?
| Immunologic Memory | 1 | 2007 | 32 | 0.080 |
Why?
| DNA Primers | 2 | 2004 | 225 | 0.080 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 206 | 0.080 |
Why?
| Th1 Cells | 1 | 2007 | 50 | 0.080 |
Why?
| Radiopharmaceuticals | 1 | 2008 | 242 | 0.080 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 106 | 0.070 |
Why?
| Spondylitis, Ankylosing | 1 | 2006 | 11 | 0.070 |
Why?
| Interleukin-8 | 2 | 2005 | 99 | 0.070 |
Why?
| Chemotaxis | 2 | 2003 | 28 | 0.070 |
Why?
| Models, Biological | 2 | 2008 | 825 | 0.070 |
Why?
| Halogenated Diphenyl Ethers | 1 | 2006 | 1 | 0.070 |
Why?
| Inflammation Mediators | 1 | 2007 | 128 | 0.070 |
Why?
| Steroid 11-beta-Hydroxylase | 1 | 2006 | 1 | 0.070 |
Why?
| Hemostasis, Endoscopic | 1 | 2006 | 4 | 0.070 |
Why?
| Ligation | 4 | 2008 | 64 | 0.070 |
Why?
| Time Factors | 2 | 2010 | 3210 | 0.070 |
Why?
| Gastroscopy | 1 | 2005 | 18 | 0.070 |
Why?
| RNA, Messenger | 5 | 2014 | 1203 | 0.070 |
Why?
| Pilot Projects | 2 | 2005 | 807 | 0.070 |
Why?
| Proto-Oncogene Proteins | 2 | 2008 | 169 | 0.070 |
Why?
| Ketotifen | 1 | 2005 | 2 | 0.070 |
Why?
| Macrophages | 1 | 2008 | 404 | 0.070 |
Why?
| Leukotriene Antagonists | 1 | 2005 | 5 | 0.070 |
Why?
| Histamine H1 Antagonists | 1 | 2005 | 9 | 0.070 |
Why?
| Case-Control Studies | 3 | 2014 | 1229 | 0.070 |
Why?
| Cytokines | 1 | 2009 | 677 | 0.070 |
Why?
| Caspase 8 | 1 | 2005 | 16 | 0.070 |
Why?
| Fas Ligand Protein | 1 | 2005 | 21 | 0.070 |
Why?
| Quinolines | 1 | 2005 | 40 | 0.070 |
Why?
| BH3 Interacting Domain Death Agonist Protein | 1 | 2005 | 15 | 0.070 |
Why?
| Anti-Asthmatic Agents | 1 | 2005 | 31 | 0.070 |
Why?
| Genes, Bacterial | 1 | 2005 | 67 | 0.070 |
Why?
| Chromatin | 1 | 2006 | 156 | 0.070 |
Why?
| Hydrolysis | 1 | 2005 | 68 | 0.060 |
Why?
| Diet | 1 | 2009 | 598 | 0.060 |
Why?
| Chemokines | 1 | 2005 | 96 | 0.060 |
Why?
| Acetates | 1 | 2005 | 50 | 0.060 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 21 | 0.060 |
Why?
| Anesthesia, Inhalation | 1 | 2004 | 13 | 0.060 |
Why?
| Midazolam | 1 | 2004 | 42 | 0.060 |
Why?
| Cytochromes c | 1 | 2004 | 41 | 0.060 |
Why?
| Cholesterol | 1 | 2005 | 155 | 0.060 |
Why?
| Methyl Ethers | 1 | 2004 | 18 | 0.060 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2004 | 43 | 0.060 |
Why?
| Kaplan-Meier Estimate | 2 | 2021 | 514 | 0.060 |
Why?
| Anesthetics, Intravenous | 1 | 2004 | 26 | 0.060 |
Why?
| DNA Fragmentation | 1 | 2004 | 67 | 0.060 |
Why?
| Chronic Disease | 1 | 2007 | 614 | 0.060 |
Why?
| Receptors, Interleukin-2 | 1 | 2004 | 7 | 0.060 |
Why?
| Antibodies, Blocking | 1 | 2004 | 8 | 0.060 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 6 | 0.060 |
Why?
| Immunotoxins | 1 | 2004 | 5 | 0.060 |
Why?
| Gene Expression | 1 | 2007 | 664 | 0.060 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2004 | 12 | 0.060 |
Why?
| Coculture Techniques | 1 | 2004 | 159 | 0.060 |
Why?
| Esophagoscopy | 1 | 2004 | 26 | 0.060 |
Why?
| Tranexamic Acid | 1 | 2004 | 17 | 0.060 |
Why?
| Patient Compliance | 1 | 2005 | 247 | 0.060 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 36 | 0.060 |
Why?
| Interleukin-2 | 1 | 2004 | 75 | 0.060 |
Why?
| Leukocytes, Mononuclear | 2 | 2015 | 133 | 0.060 |
Why?
| Cystitis | 1 | 2004 | 18 | 0.060 |
Why?
| Pancreatic Pseudocyst | 1 | 2003 | 7 | 0.060 |
Why?
| Protozoan Proteins | 1 | 2004 | 31 | 0.060 |
Why?
| Jaundice, Obstructive | 1 | 2003 | 8 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2004 | 141 | 0.060 |
Why?
| Protein Processing, Post-Translational | 1 | 2005 | 183 | 0.060 |
Why?
| Body Weight | 1 | 2006 | 578 | 0.060 |
Why?
| Lidocaine | 1 | 2003 | 48 | 0.060 |
Why?
| Recombinant Fusion Proteins | 1 | 2004 | 206 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2004 | 198 | 0.060 |
Why?
| Anesthetics, Local | 1 | 2003 | 74 | 0.060 |
Why?
| Cell Division | 1 | 2004 | 330 | 0.060 |
Why?
| Hemorrhage | 1 | 2004 | 209 | 0.060 |
Why?
| Polymerase Chain Reaction | 1 | 2004 | 531 | 0.060 |
Why?
| Oocytes | 1 | 2003 | 94 | 0.050 |
Why?
| Recombinant Proteins | 1 | 2004 | 570 | 0.050 |
Why?
| Phencyclidine | 1 | 2002 | 21 | 0.050 |
Why?
| Amphetamines | 1 | 2002 | 28 | 0.050 |
Why?
| Acute Disease | 3 | 2008 | 403 | 0.050 |
Why?
| Parkinsonian Disorders | 1 | 2001 | 15 | 0.050 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2002 | 51 | 0.050 |
Why?
| Dinoprostone | 2 | 2014 | 55 | 0.050 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 2001 | 65 | 0.050 |
Why?
| Hepatocytes | 2 | 2013 | 214 | 0.050 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2001 | 83 | 0.050 |
Why?
| Dopamine Uptake Inhibitors | 1 | 2002 | 61 | 0.050 |
Why?
| Asthma | 1 | 2005 | 293 | 0.050 |
Why?
| Proteins | 1 | 2004 | 376 | 0.050 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 121 | 0.050 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 176 | 0.050 |
Why?
| Infusions, Intra-Arterial | 2 | 2014 | 18 | 0.050 |
Why?
| Molecular Targeted Therapy | 1 | 2021 | 128 | 0.050 |
Why?
| Mitomycin | 2 | 2014 | 23 | 0.050 |
Why?
| Hepatic Artery | 2 | 2014 | 25 | 0.050 |
Why?
| Fluorouracil | 2 | 2014 | 61 | 0.050 |
Why?
| Hepatitis B Surface Antigens | 2 | 2013 | 10 | 0.050 |
Why?
| Disease Management | 1 | 2021 | 184 | 0.040 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 216 | 0.040 |
Why?
| Transfection | 2 | 2013 | 399 | 0.040 |
Why?
| Lymphocytes | 1 | 2020 | 168 | 0.040 |
Why?
| Neutrophils | 1 | 2020 | 154 | 0.040 |
Why?
| Inflammation | 1 | 2003 | 678 | 0.040 |
Why?
| Predictive Value of Tests | 2 | 2012 | 1045 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2019 | 252 | 0.040 |
Why?
| Reference Values | 2 | 2012 | 354 | 0.040 |
Why?
| Cell Movement | 3 | 2003 | 271 | 0.040 |
Why?
| Incidence | 2 | 2014 | 1083 | 0.040 |
Why?
| Calcium | 3 | 2003 | 434 | 0.040 |
Why?
| Brain | 2 | 2002 | 1392 | 0.040 |
Why?
| Probability | 2 | 2009 | 177 | 0.040 |
Why?
| Amino Acid Sequence | 2 | 2010 | 767 | 0.030 |
Why?
| Smoke | 1 | 2015 | 21 | 0.030 |
Why?
| Interferon-alpha | 1 | 2014 | 50 | 0.030 |
Why?
| Fluorescent Antibody Technique | 1 | 2014 | 141 | 0.030 |
Why?
| Early Detection of Cancer | 1 | 2015 | 164 | 0.030 |
Why?
| Hepatitis B e Antigens | 1 | 2013 | 2 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2014 | 166 | 0.030 |
Why?
| Drug Resistance, Viral | 1 | 2013 | 8 | 0.030 |
Why?
| Viral Load | 1 | 2014 | 86 | 0.030 |
Why?
| Appendectomy | 1 | 2014 | 41 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2014 | 134 | 0.030 |
Why?
| Depression, Chemical | 2 | 2003 | 15 | 0.030 |
Why?
| Adenoviridae | 1 | 2013 | 58 | 0.030 |
Why?
| Pelvis | 1 | 2014 | 77 | 0.030 |
Why?
| PPAR gamma | 1 | 2014 | 81 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 206 | 0.030 |
Why?
| Abdomen | 1 | 2014 | 84 | 0.030 |
Why?
| Immunophenotyping | 1 | 2013 | 117 | 0.030 |
Why?
| Neoplastic Stem Cells | 1 | 2014 | 104 | 0.030 |
Why?
| Proportional Hazards Models | 2 | 2004 | 430 | 0.030 |
Why?
| Genetic Vectors | 1 | 2013 | 139 | 0.030 |
Why?
| Genome, Viral | 1 | 2013 | 100 | 0.030 |
Why?
| Promoter Regions, Genetic | 2 | 2006 | 520 | 0.030 |
Why?
| Dependovirus | 1 | 2013 | 102 | 0.030 |
Why?
| Albuterol | 2 | 2003 | 58 | 0.030 |
Why?
| Elasticity | 1 | 2012 | 30 | 0.030 |
Why?
| Tomography, X-Ray Computed | 2 | 2009 | 1222 | 0.030 |
Why?
| Platelet Count | 1 | 2012 | 77 | 0.030 |
Why?
| Blotting, Western | 1 | 2014 | 684 | 0.030 |
Why?
| Antineoplastic Agents | 1 | 2021 | 1300 | 0.030 |
Why?
| Ubiquitination | 1 | 2012 | 47 | 0.030 |
Why?
| Liver Function Tests | 1 | 2012 | 43 | 0.030 |
Why?
| Alanine Transaminase | 1 | 2012 | 151 | 0.030 |
Why?
| RNA, Small Interfering | 1 | 2012 | 253 | 0.030 |
Why?
| Dopamine | 2 | 2003 | 190 | 0.030 |
Why?
| Base Sequence | 1 | 2012 | 719 | 0.020 |
Why?
| Drug Resistance, Bacterial | 1 | 2011 | 81 | 0.020 |
Why?
| Blotting, Southern | 1 | 2010 | 40 | 0.020 |
Why?
| Blotting, Northern | 1 | 2010 | 108 | 0.020 |
Why?
| Cerebral Cortex | 2 | 2002 | 234 | 0.020 |
Why?
| Sequence Deletion | 1 | 2010 | 99 | 0.020 |
Why?
| Hyperamylasemia | 1 | 2008 | 1 | 0.020 |
Why?
| Fatty Alcohols | 1 | 2008 | 2 | 0.020 |
Why?
| Mice, Inbred ICR | 1 | 2008 | 25 | 0.020 |
Why?
| I-kappa B Proteins | 1 | 2008 | 26 | 0.020 |
Why?
| Metabolic Clearance Rate | 1 | 2009 | 75 | 0.020 |
Why?
| Radionuclide Imaging | 1 | 2009 | 134 | 0.020 |
Why?
| Hyperplasia | 1 | 2008 | 107 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 101 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2009 | 232 | 0.020 |
Why?
| Liver Regeneration | 1 | 2008 | 57 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2009 | 231 | 0.020 |
Why?
| Bacterial Infections | 1 | 2009 | 105 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 153 | 0.020 |
Why?
| Cell Nucleus | 1 | 2008 | 203 | 0.020 |
Why?
| Mucous Membrane | 1 | 2007 | 33 | 0.020 |
Why?
| Duodenum | 1 | 2007 | 36 | 0.020 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 208 | 0.020 |
Why?
| Esophagus | 1 | 2007 | 80 | 0.020 |
Why?
| Nitric Oxide | 1 | 2009 | 298 | 0.020 |
Why?
| Flavones | 1 | 2006 | 5 | 0.020 |
Why?
| Dactinomycin | 1 | 2006 | 23 | 0.020 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2006 | 29 | 0.020 |
Why?
| S100 Proteins | 1 | 2006 | 41 | 0.020 |
Why?
| RNA Processing, Post-Transcriptional | 1 | 2006 | 29 | 0.020 |
Why?
| DNA, Complementary | 1 | 2006 | 145 | 0.020 |
Why?
| Treatment Failure | 1 | 2006 | 141 | 0.020 |
Why?
| Chemokine CCL17 | 1 | 2005 | 1 | 0.020 |
Why?
| Chemokine CCL22 | 1 | 2005 | 2 | 0.020 |
Why?
| Emergencies | 1 | 2006 | 92 | 0.020 |
Why?
| Peak Expiratory Flow Rate | 1 | 2005 | 8 | 0.020 |
Why?
| Cyclopropanes | 1 | 2005 | 19 | 0.020 |
Why?
| Sulfides | 1 | 2005 | 32 | 0.020 |
Why?
| Acids | 1 | 2005 | 11 | 0.020 |
Why?
| Th2 Cells | 1 | 2005 | 26 | 0.020 |
Why?
| Respiratory Function Tests | 1 | 2005 | 98 | 0.020 |
Why?
| Stress, Psychological | 1 | 2007 | 270 | 0.020 |
Why?
| Skin | 1 | 2008 | 469 | 0.020 |
Why?
| Hemostasis, Surgical | 1 | 2004 | 12 | 0.020 |
Why?
| alpha-Fetoproteins | 1 | 2004 | 15 | 0.020 |
Why?
| Drug Resistance | 1 | 2005 | 75 | 0.020 |
Why?
| Hepatitis C Antibodies | 1 | 2004 | 21 | 0.020 |
Why?
| Leucovorin | 1 | 2004 | 18 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2005 | 194 | 0.020 |
Why?
| Hepatectomy | 1 | 2004 | 33 | 0.020 |
Why?
| RNA | 1 | 2006 | 202 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2008 | 1141 | 0.020 |
Why?
| Endoscopes, Gastrointestinal | 1 | 2004 | 3 | 0.020 |
Why?
| Omeprazole | 1 | 2004 | 17 | 0.020 |
Why?
| Transcription Factors | 1 | 2008 | 622 | 0.020 |
Why?
| Cardiolipins | 1 | 2004 | 1 | 0.020 |
Why?
| Dizziness | 1 | 2004 | 13 | 0.020 |
Why?
| Virulence Factors | 1 | 2005 | 94 | 0.020 |
Why?
| Hydronephrosis | 1 | 2004 | 14 | 0.020 |
Why?
| Pancreatitis, Alcoholic | 1 | 2003 | 3 | 0.010 |
Why?
| Exanthema | 1 | 2004 | 36 | 0.010 |
Why?
| Chemokine CCL4 | 1 | 2003 | 4 | 0.010 |
Why?
| Ribosomal Proteins | 1 | 2004 | 32 | 0.010 |
Why?
| Chemokine CCL3 | 1 | 2003 | 7 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 124 | 0.010 |
Why?
| Double-Blind Method | 1 | 2005 | 743 | 0.010 |
Why?
| Autoantibodies | 1 | 2004 | 135 | 0.010 |
Why?
| Survival Analysis | 1 | 2004 | 736 | 0.010 |
Why?
| Dopamine Antagonists | 1 | 2002 | 19 | 0.010 |
Why?
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2001 | 8 | 0.010 |
Why?
| L-Lactate Dehydrogenase | 1 | 2002 | 79 | 0.010 |
Why?
| Binding, Competitive | 1 | 2002 | 113 | 0.010 |
Why?
| Neostriatum | 1 | 2001 | 13 | 0.010 |
Why?
| Tyrosine 3-Monooxygenase | 1 | 2001 | 16 | 0.010 |
Why?
| Glycine | 1 | 2002 | 70 | 0.010 |
Why?
| Cell Death | 1 | 2002 | 223 | 0.010 |
Why?
| Cell Membrane | 1 | 2002 | 279 | 0.010 |
Why?
| Cerebellum | 1 | 2001 | 142 | 0.010 |
Why?
| Kinetics | 1 | 2002 | 692 | 0.010 |
Why?
| Postoperative Complications | 1 | 2004 | 1035 | 0.010 |
Why?
| Child | 1 | 2005 | 7368 | 0.010 |
Why?
|
|
Hsu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|